The Use of TauPET & Blood GFAP in Clinical Trials & Practice to Enable Earlier Change Detection & Smaller Alzheimer’s Trials

• Leveraging biomarker stratification and early change detection through integrated analysis of cognitive and functional scores to reduce trial duration and enhance patient engagement.
• How close are Tau PET and blood GFAP being accepted as primary end‑points to enable smaller sample sizes once validated?

Speakers:

Tharick A Pascoal

Associate Professor of Psychiatry & Neurology

University of Pittsburgh School of Medicine